Nadia M. Chu

Nadia M. Chu

Auto-generated profile, based on publicly available information

Nadia M. Chu

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2018 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
MMMara A. McAdams‐DeMarco
Mara A. McAdams‐DeMarco
HYHao Ying
Hao Ying
SRSarah Van Pilsum Rasmussen
Sarah Van Pilsum Rasmussen
JSJennifer Schrack
Jennifer Schrack
CHChristine E. Haugen
Christine E. Haugen
DSDorry L. Segev
Dorry L. Segev

19 March 2019 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
CHChristine E. Haugen
Christine E. Haugen
NCNadia M. Chu
Nadia M. Chu
HYHao Ying
Hao Ying
FWFatima Warsame
Fatima Warsame
CHCourtenay M. Holscher
Courtenay M. Holscher
MMMara McAdams-DeMarco
Mara McAdams-DeMarco
Background and objectives Frailty, a syndrome distinct from comorbidity and disability, is clinically manifested as a decreased resistance to stressors and is present in up to 35% of patient with ESKD. It is associated with falls, hospitalizations, poor cognitive function, and mortality. Also, frailty is associated with poor outcomes after kidney transplant, including delirium and mortality. Frailty is likely also associated with decreased access to kidney transplantation, given its association with poor outcomes on dialysis and post-transplant. Yet, clinicians have difficulty identifying which patients are frail; therefore, we sought to quantify if frail kidney transplant candidates had similar access to kidney transplantation as nonfrail candidates. Design, setting, participants, & measurements We studied 7078 kidney transplant candidates (2009–2018) in a three-center prospective cohort study of frailty. Fried frailty (unintentional weight loss, grip strength, walking speed, exhaustion, and activity level) was measured at outpatient kidney transplant evaluation. We estimated time to listing and transplant rate by frailty status using Cox proportional hazards and Poisson regression, adjusting for demographic and health factors. Results The mean age was 54 years (SD 13; range, 18–89), 40% were women, 34% were black, and 21% were frail. Frail participants were almost half as likely to be listed for kidney transplantation (hazard ratio, 0.62; 95% confidence interval, 0.56 to 0.69; P<0.001) compared with nonfrail participants, independent of age and other demographic factors. Furthermore, frail candidates were transplanted 32% less frequently than nonfrail candidates (incidence rate ratio, 0.68; 95% confidence interval, 0.58 to 0.81; P<0.001). Conclusions Frailty is associated with lower chance of listing and lower rate of transplant, and is a potentially modifiable risk factor. Visual Abstract

24 January 2019 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
NCNadia M. Chu
Nadia M. Chu
AGAlden L. Gross
Alden L. Gross
ASAshton A. Shaffer
Ashton A. Shaffer
CHChristine E. Haugen
Christine E. Haugen
SNSilas P. Norman
Silas P. Norman
MMMara A. McAdams-DeMarco
Mara A. McAdams-DeMarco
Significance Statement: Frailty is a predictor of adverse outcomes in kidney transplant populations. Although restoration of kidney function after transplant generally improves cognitive function, it seems plausible that, in frail individuals, stressors related to surgery and immunosuppression might mitigate short-term cognitive improvement and contribute to possible subsequent decline. The authors found significantly lower pretransplant cognitive scores in frail kidney transplant recipients compared with nonfrail recipients. Although both groups showed cognitive improvement by 3 months post-transplant, cognitive function plateaued for nonfrail recipients between 1 and 4 years after transplant and declined for frail recipients. By 4 years post-transplant, cognitive scores were significantly lower among frail versus nonfrail recipients. Transplant centers are encouraged to apply available evidence-based strategies to reduce risk of cognitive impairment among frail transplant recipients. Background: Restoration of kidney function after kidney transplant generally improves cognitive function. It is unclear whether frail recipients, with higher susceptibility to surgical stressors, achieve such post-transplant cognitive improvements or whether they experience subsequent cognitive decline as they age with a functioning graft. Methods: In this two-center cohort study, we assessed pretransplant frailty (Fried physical frailty phenotype) and cognitive function (Modified Mini-Mental State Examination) in adult kidney transplant recipients. To investigate potential short- and medium-term effects of frailty on post-transplant cognitive trajectories, we measured cognitive function up to 4 years post-transplant. Using an adjusted mixed effects model with a random slope (time) and intercept (person), we characterized post-transplant cognitive trajectories by pretransplant frailty, accounting for nonlinear trajectories. Results: Of 665 recipients (mean age 52.0 years) followed for a median of 1.5 years, 15.0% were frail. After adjustment, pretransplant cognitive scores were significantly lower among frail patients compared with nonfrail patients (89.0 versus 90.8 points). By 3 months post-transplant, cognitive performance improved for both frail (slope =0.22 points per week) and nonfrail (slope =0.14 points per week) recipients. Between 1 and 4 years post-transplant, improvements plateaued among nonfrail recipients (slope =0.005 points per week), whereas cognitive function declined among frail recipients (slope =−0.04 points per week). At 4 years post-transplant, cognitive scores were 5.8 points lower for frail recipients compared with nonfrail recipients. Conclusions: On average, both frail and nonfrail recipients experience short-term cognitive improvement post-transplant. However, frailty is associated with medium-term cognitive decline post-transplant. Interventions to prevent cognitive decline among frail recipients should be identified.

25 November 2021 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
NCNadia M Chu
Nadia M Chu
JHJingyao Hong
Jingyao Hong
OHOksana Harasemiw
Oksana Harasemiw
XCXiaomeng Chen
Xiaomeng Chen
KFKevin J Fowler
Kevin J Fowler
TNthe Global Renal Exercise Network
the Global Renal Exercise Network
Cognitive impairment is common among persons with chronic kidney disease (CKD), due in part to reduced kidney function. Given that physical activity (PA) is known to mitigate cognitive decline, we examined whether associations between CKD stage and global/domain-specific cognitive function differ by PA. We leveraged 3223 participants (≥60 years of age) enrolled in National Health and Nutrition Examination Survey (NHANES, 2011–2014), with at least one measure of objective cognitive function [immediate recall (CERAD-WL), delayed recall (CERAD-DR), verbal fluency (AF), executive function/processing speed (DSST), global (average of four tests) or self-perceived memory decline (SCD)]. We quantified the association between CKD stage {no CKD: estimated glomerular filtration rate [eGFR] ≥60 mL/min/1.73 m2 and albuminuria [albumin:creatinine ratio (ACR)] <30 mg/g; stages G1–G3: eGFR ≥60 mL/min/1.73 m2 and ACR ≥30 mg/g or eGFR 30–59 mL/min/1.73 m2; stages G4 and G5: eGFR <30 mL/min/1.73 m2} and cognitive function using linear regression (objective measures) and logistic regression (SCD), accounting for sampling weights for nationally representative estimates. We tested whether associations differed by PA [Global Physical Activity Questionnaire, high PA ≥600 metabolic equivalent of task (MET) · min/week versus low PA <600 MET · min/week] using a Wald test. Among NHANES participants, 34.9% had CKD stages G1–G3, 2.6% had stages G4 and G5 and 50.7% had low PA. CKD stages G4 and G5 were associated with lower global cognitive function {difference = −0.38 standard deviation [SD] [95% confidence interval (CI) −0.62 to −0.15]}. This association differed by PA (Pinteraction = 0.01). Specifically, among participants with low PA, those with CKD stages G4 and G5 had lower global cognitive function [difference = −0.57 SD (95% CI −0.82 to −0.31)] compared with those without CKD. Among those with high PA, no difference was found [difference = 0.10 SD (95% CI −0.29–0.49)]. Similarly, the CKD stage was only associated with immediate recall, verbal fluency, executive function and processing speed among those with low PA; no associations were observed for delayed recall or self-perceived memory decline. CKD is associated with lower objective cognitive function among those with low but not high PA. Clinicians should consider screening older patients with CKD who have low PA for cognitive impairment and encourage them to meet PA guidelines.

8 July 2020 in American Journal of Nephrology
Verified
Journal Article
Open access
PDF file
NCNadia M. Chu
Nadia M. Chu
XCXiaomeng Chen
Xiaomeng Chen
SNSilas P. Norman
Silas P. Norman
JFJessica Fitzpatrick
Jessica Fitzpatrick
SSStephen M. Sozio
Stephen M. Sozio
MMMara A. McAdams-DeMarco
Mara A. McAdams-DeMarco
Background: Frailty, originally characterized in community-dwelling older adults, is increasingly being studied and implemented for adult patients with end-stage kidney disease (ESKD) of all ages (>18 years). Frailty prevalence and manifestation are unclear in younger adults (18–64 years) with ESKD; differences likely exist based on whether the patients are treated with hemodialysis (HD) or kidney transplantation (KT). Methods: We leveraged 3 cohorts: 378 adults initiating HD (2008–2012), 4,304 adult KT candidates (2009–2019), and 1,396 KT recipients (2008–2019). The frailty phenotype was measured within 6 months of dialysis initiation, at KT evaluation, and KT admission. Prevalence of frailty and its components was estimated by age (≥65 vs. <65 years). A Wald test for interactions was used to test whether risk factors for frailty differed by age. Results: In all 3 cohorts, frailty prevalence was higher among older than younger adults (HD: 71.4 vs. 47.3%; candidates: 25.4 vs. 18.8%; recipients: 20.8 vs. 14.3%). In all cohorts, older patients were more likely to have slowness and weakness but less likely to report exhaustion. Among candidates, older age (odds ratio [OR] = 1.79, 95% CI: 1.47–2.17), non-Hispanic black race (OR = 1.30, 95% CI: 1.08–1.57), and dialysis type (HD vs. no dialysis: OR = 2.06, 95% CI: 1.61–2.64; peritoneal dialysis vs. no dialysis: OR = 1.78, 95% CI: 1.28–2.48) were associated with frailty prevalence, but sex and Hispanic ethnicity were not. These associations did not differ by age (pinteractions > 0.1). Similar results were observed for recipients and HD patients. Conclusions: Although frailty prevalence increases with age, younger patients have a high burden. Clinicians caring for this vulnerable population should recognize that younger patients may experience frailty and screen all age groups.

9 January 2019 in American Journal of Nephrology
Verified
Journal Article
Closed access
PDF file
MFMaría Pérez Fernández
María Pérez Fernández
PMPatricia Martínez Miguel
Patricia Martínez Miguel
HYHao Ying
Hao Ying
CHChristine E. Haugen
Christine E. Haugen
NCNadia M. Chu
Nadia M. Chu
MMMara A. McAdams-DeMarco
Mara A. McAdams-DeMarco
Background: Kidney transplantation (KT) candidates often present with multiple comorbidities. These patients also have a substantial burden of frailty, which is also associated with increased mortality. However, it is unknown if frailty is merely a surrogate for comorbidity, itself an independent domain of risk, or if frailty and comorbidity have differential effects. Better understanding the interplay between these 2 constructs will improve clinical decision making in KT candidates. Objective: To test whether comorbidity is equally associated with waitlist mortality among frail and nonfrail KT candidates and to test whether measuring both comorbidity burden and frailty improves mortality risk prediction. Methods: We studied 2,086 candidates on the KT waitlist (November 2009 – October 2017) in a multicenter cohort study, in whom frailty and comorbidity were measured at evaluation. We quantified the association between Charlson comorbidity index (CCI) adapted for end-stage renal disease and waitlist mortality using an adjusted Cox proportional hazards model and tested whether this association differed between frail and nonfrail candidates. Results: At evaluation, 18.1% of KT candidates were frail and 51% had a high comorbidity burden (CCI score ≥2). Candidates with a high comorbidity burden were at 1.38-fold (95% CI 1.01–1.89) increased risk of waitlist mortality. However, this association differed by frailty status (p for interaction = 0.01): among nonfrail candidates, a high comorbidity burden was associated with a 1.66-fold (95% CI 1.17–2.35) increased mortality risk; among frail candidates, here was no statistically significant association (HR 0.75, 95% CI 0.44–1.29). Adding this interaction between comorbidity and frailty to a mortality risk estimation model significantly improved prediction, increasing the c-statistic from 0.640 to 0.656 (p < 0.001). Conclusions: Nonfrail candidates with a high comorbidity burden at KT evaluation have an increased risk of waitlist mortality. Importantly, comorbidity is less of a concern in already high-risk patients who are frail.